---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-007678"
form_type: "8-K"
ticker: "SIGA"
cik: "0001010086"
company_name: "SIGA TECHNOLOGIES INC"
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:49:24.059014+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX

## Summary
- FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.
- Q4 2021 revenues $115.4M ($73.2M net income, $0.98 EPS) driven by $113M U.S. delivery of oral TPOXX.
- International product sales $13M in 2021, up from $2M; EMA approved oral TPOXX in Jan 2022, Health Canada in Dec 2021.
- SIGA repurchased ~3.8M shares for $26M in 2021 (~5% of shares outstanding); collaboration with Bioarchitech on immunotherapy.

## SEC filing metadata
- accession: 0001140361-22-007678
- form_type: 8-K
- ticker: SIGA
- cik: 0001010086
- company_name: SIGA TECHNOLOGIES INC
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1010086/000114036122007678/0001140361-22-007678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1010086/000114036122007678/brhc10034763_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-007678
- JSON: https://secwatch.observer/filing/0001140361-22-007678.json
- Plain text: https://secwatch.observer/filing/0001140361-22-007678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.